Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CSL ( (AU:CSL) ).
CSL Limited announced a change in the interests of Dr. Paul McKenzie, a director of the company, involving the grant of 58,360 Performance Share Units as part of a long-term incentive plan. This change, approved by shareholders at the 2025 Annual General Meeting, is intended to align the director’s interests with the company’s long-term performance goals, potentially impacting CSL’s strategic direction and stakeholder confidence.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$212.10 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative medicines. The company is known for its production of vaccines, blood plasma derivatives, and other biopharmaceutical products, serving a global market with a strong emphasis on addressing unmet medical needs.
Average Trading Volume: 1,296,226
Technical Sentiment Signal: Sell
Current Market Cap: A$82.85B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.